All In Biotech

Drug Trial Radar · NCT07901595

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes

A Phase 1/2a, First-in-human, Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile and the Effect of Food of Oral PAL-119 in Healthy Volunteers and in Adult Participants With Type 1 or Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

147

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Nov 1, 2027

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Paulex Bio Inc.Industry
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.

Conditions

  • Healthy Volunteers and Diabetes Participants

Interventions

  • PAL-119Drug

    Small synthetic molecule

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Part 1: Safety and tolerability of PAL-119 in healthy volunteersTime frame: 8 days
  2. Phase 1 Part 2: Safety and tolerability of PAL-119 in healthy volunteersTime frame: 17 days
  3. Phase 1 Part 3: Safety and tolerability of PAL-119 in healthy volunteersTime frame: 8 days
  4. Phase 2 Part 4: Safety and tolerability of PAL-119 in adult participants with Type 2 diabetesTime frame: 17 weeks
  5. Phase 2 Part 4: Incidence and severity of hypoglycemic episodes in adult participants with Type 2 diabetesTime frame: 17 weeks
  6. Phase 2 Part 5: Safety and tolerability of PAL-119 in adult participants with Type 1 diabetesTime frame: 17 weeks
  7. Phase 2 Part 5: Incidence and severity of hypoglycemic episodes in adult participants with Type 1 diabetesTime frame: 17 weeks
  8. Phase 2 Part 5: Incidence and severity of diabetic ketoacidosis and episodes of hyperglycemia with ketonemia not meeting diagnostic criteria for diabetic ketoacidosis in adult participants with Type 1 diabetesTime frame: 17 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.